Image text and data — Historical medicines regulator banner
The image is a banner for the medicines section of the former China Food and Drug Administration (CFDA). It does not itself contain a clinical-trial approval, approval number or approval date; the event is described in the accompanying article.
On 28 June 2018, the National Medical Products Administration, formerly the China Food and Drug Administration, issued clinical trial approval for Innogen’s efsubaglutide alfa injection. In accordance with national regulations, the medicine had completed Phase I and entered Phase II at the time of this report. The company aimed to complete its planned Phase III research as quickly as possible and provide an innovative diabetes medicine meeting international standards, with independently owned intellectual property, high quality and efficacy, and a low price.